Overview A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2 Status: Withdrawn Trial end date: 2014-08-01 Target enrollment: Participant gender: Summary maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in diabetes type II Phase: Phase 4 Details Lead Sponsor: AbbottCollaborators: CatalentClinIntelDatamapNuvisanTreatments: PancreatinPancrelipase